EU approves life changing 'important' Alzheimer's drug which can drastically slow onset
Lecanemab is the first treatment for Alzheimer’s disease licensed for use in Great Britain that shows some evidence of ...
Life-changing Alzheimer's drug approved for use in EU to reduce cognitive decline
A groundbreaking medication designed to delay the onset of Alzheimer's has received approval for use within the EU. The drug, ...
Japan Today8h
Japan approves 2nd protein-targeting drug for Alzheimer's sufferers
A single course of newly approved Alzheimer's drug donanemab-azbt, the second medicine available in Japan targeting proteins in the brains of sufferers of the debilitating disease, will cost 3.08 ...
Worldcrunch on MSN12h
Lecanemab: Why This Could Be The Beginning Of The End Of Alzheimer’s
The first drug targeting the root cause of Alzheimer’s disease has been approved by the European Medicines Agency. Despite ...
Medscape13h
Leqembi Okayed for Subset of Early Alzheimer’s Patients
The European Medicines Agency re-examined clinical data of a subset of patients with one or no copies of the APOE4 gene ...
Zacks.com on MSN15h
Biogen Partner Eisai Gets Positive CHMP Nod for Leqembi in Europe
Biogen Inc.’s BIIB Japan-based partner, Eisai announced that the European Medicines Agency’s (EMA) Committee for Medicinal ...
Ticker: Biogen Alzheimer’s drug gets second look in EU; Ford takes $165M hit on slow recall
A European regulatory committee now recommends approval of the Alzheimer’s treatment lecanemab a few months after rejecting ...
EU regulator reverses decision to block Alzheimer's drug lecanemab
The European Union's drugs regulator reversed its decision to block the Alzheimer's drug lecanemab, a treatment aimed at ...
Eisai receives positive CHMP opinion for Lecanemab in early Alzheimer’s disease
Eisai (ESAIY) and Biogen (BIIB) announced that a positive opinion has been received from the Committee for Medicinal Products for Human Use of ...
European committee takes a second look at Alzheimer’s drug and now says it should be approved
A European regulatory committee now recommends approval of the Alzheimer’s treatment lecanemab a few months after rejecting ...
European watchdog partially approves new Alzheimer's drug
Europe's medicines watchdog on Thursday partially approved a marketing request for a long-awaited new treatment for Alzheimer ...
Biogen's stock rises after E.U. regulator reverses negative view of Alzheimer's drug
Biogen Inc.'s stock rose 1% Thursday, after Europe's pharmaceutical regulator issued a positive opinion on the Alzheimer's disease drug that the company developed with Japanese partner Eisai - ...